PIM1 and pulmonary arterial hypertension: Regardless of these limitations and confounding factors, our findings identify novel genetic variants associated with PAH and provide further support for the notion of repositioning PIM1 inhibitors like TP-3654, which was originally developed for advanced solid tumors (Lampron et al., 2020), for the treatment of PAH, possibly in conjunction with PIM1 detection in pulmonary vasculature or elevated plasma PIM1 levels.